Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
Au L, Fendler A, Shepherd STC, Rzeniewicz K, Cerrone M, Byrne F, Carlyle E, Edmonds K, Del Rosario L, Shon J, Haynes WA, Ward B, Shum B, Gordon W, Gerard CL, Xie W, Joharatnam-Hogan N, Young K, Pickering L, Furness AJS, Larkin J, Harvey R, Kassiotis G, Gandhi S; Crick COVID-19 Consortium; Swanton C, Fribbens C, Wilkinson KA, Wilkinson RJ, Lau DK, Banerjee S, Starling N, Chau I; CAPTURE Consortium; Turajlic S. Au L, et al. Among authors: lau dk. Nat Med. 2021 Aug;27(8):1362-1366. doi: 10.1038/s41591-021-01387-6. Epub 2021 May 26. Nat Med. 2021. PMID: 34040262 Free PMC article.
Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study.
Lau D, Kalaitzaki E, Church DN, Pandha H, Tomlinson I, Annels N, Gerlinger M, Sclafani F, Smith G, Begum R, Crux R, Gillbanks A, Wordsworth S, Chau I, Starling N, Cunningham D, Dhillon T. Lau D, et al. ESMO Open. 2020 Feb;5(1):e000638. doi: 10.1136/esmoopen-2019-000638. ESMO Open. 2020. PMID: 32079623 Free PMC article. Clinical Trial.
HER2 targeted therapy in colorectal cancer: New horizons.
Suwaidan AA, Lau DK, Chau I. Suwaidan AA, et al. Among authors: lau dk. Cancer Treat Rev. 2022 Apr;105:102363. doi: 10.1016/j.ctrv.2022.102363. Epub 2022 Feb 22. Cancer Treat Rev. 2022. PMID: 35228040 Review.
Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.
Lau DK, Fong C, Arouri F, Cortez L, Katifi H, Gonzalez-Exposito R, Razzaq MB, Li S, Macklin-Doherty A, Hernandez MA, Hubank M, Fribbens C, Watkins D, Rao S, Chau I, Cunningham D, Starling N. Lau DK, et al. BMC Cancer. 2023 Apr 26;23(1):380. doi: 10.1186/s12885-023-10857-8. BMC Cancer. 2023. PMID: 37101114 Free PMC article.
Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Chionh F, et al. Cochrane Database Syst Rev. 2017 Jul 28;7(7):CD008398. doi: 10.1002/14651858.CD008398.pub2. Cochrane Database Syst Rev. 2017. PMID: 28752564 Free PMC article. Review.
56 results